Completed PHASE3 INTERVENTIONAL 2-arm NCT01227876

Clinical Efficacy of the Drug Ster® Compared With Predfort® in Control of Postoperative Inflammation in Cataract Surgery

Assessment of Clinical Efficacy of 1% Prednisolone Acetate (Ster ®), Produced by união química, Compared to 1% Prednisolone Acetate (Pred ® Fort), Produced by Allergan, in the Control of Postoperative Inflammation in Cataract Surgery.

Sponsor: Azidus Brasil

Conditions Cataract Surgery Inflammation

Interventions Pred Fort Ster

Updated 6 times since 2017 Last updated: Oct 31, 2022 Started: Jan 31, 2011 Primary completion: Feb 28, 2011 Completion: Aug 31, 2011

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Cataract Surgery and Inflammation and is currently completed. Azidus Brasil leads this study, which shows 6 recorded versions since 2011 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Dec 2022 — Jul 2024 [monthly]

Completed PHASE3

Status: Unknown Status → Completed
Jan 2021 — Dec 2022 [monthly]

Unknown Status PHASE3
Jun 2018 — Jan 2021 [monthly]

Unknown Status PHASE3

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Unknown Status PHASE3

First recorded

Jan 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Azidus Brasil

Data source: Azidus Brasil

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Valinhos, Brazil